The 36-month beta value for LYRA is also noteworthy at -0.02. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for LYRA is 55.18M, and at present, short sellers hold a 4.90% of that float. The average trading volume of LYRA on May 14, 2025 was 1.84M shares.
LYRA) stock’s latest price update
The stock price of Lyra Therapeutics Inc (NASDAQ: LYRA) has jumped by 13.56 compared to previous close of 0.09. Despite this, the company has seen a gain of 2.10% in its stock price over the last five trading days. globenewswire.com reported 2025-05-07 that WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that the Company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the Company’s lead product candidate for CRS, at the annual Combined Otolaryngology Spring Meetings (COSM 2025) being held May 14-18 in New Orleans.
LYRA’s Market Performance
LYRA’s stock has risen by 2.10% in the past week, with a monthly rise of 0.85% and a quarterly drop of -45.45%. The volatility ratio for the week is 16.62% while the volatility levels for the last 30 days are 14.10% for Lyra Therapeutics Inc The simple moving average for the last 20 days is 6.62% for LYRA’s stock, with a simple moving average of -48.63% for the last 200 days.
Analysts’ Opinion of LYRA
Many brokerage firms have already submitted their reports for LYRA stocks, with Jefferies repeating the rating for LYRA by listing it as a “Hold.” The predicted price for LYRA in the upcoming period, according to Jefferies is $0.50 based on the research report published on May 07, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $2, previously predicting the price at $12. The rating they have provided for LYRA stocks is “Neutral” according to the report published on May 07th, 2024.
LYRA Trading at -15.54% from the 50-Day Moving Average
After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.38% of loss for the given period.
Volatility was left at 14.10%, however, over the last 30 days, the volatility rate increased by 16.62%, as shares surge +7.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.33% lower at present.
During the last 5 trading sessions, LYRA fell by -5.24%, which changed the moving average for the period of 200-days by -67.65% in comparison to the 20-day moving average, which settled at $0.1002. In addition, Lyra Therapeutics Inc saw -48.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYRA starting from Waksal Harlan, who proposed sale 145,370 shares at the price of $0.10 back on Apr 25 ’25. After this action, Waksal Harlan now owns shares of Lyra Therapeutics Inc, valued at $14,930 using the latest closing price.
Palasis Maria, the Officer of Lyra Therapeutics Inc, proposed sale 39,567 shares at $0.09 during a trade that took place back on Apr 09 ’25, which means that Palasis Maria is holding shares at $3,545 based on the most recent closing price.
Stock Fundamentals for LYRA
Current profitability levels for the company are sitting at:
- -68.92 for the present operating margin
- -10.19 for the gross margin
The net margin for Lyra Therapeutics Inc stands at -67.11. The total capital return value is set at -1.82. Equity return is now at value -195.46, with -80.40 for asset returns.
Based on Lyra Therapeutics Inc (LYRA), the company’s capital structure generated 0.9 points at debt to capital in total, while cash flow to debt ratio is standing at -1.69.
Currently, EBITDA for the company is -60.26 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 7.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.96.
Conclusion
In summary, Lyra Therapeutics Inc (LYRA) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
